{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:22:27Z","timestamp":1770290547981,"version":"3.49.0"},"reference-count":118,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T00:00:00Z","timestamp":1631923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>The novel human coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has caused a pandemic. There are currently several marketed vaccines and many in clinical trials targeting SARS-CoV-2. Another strategy is to repurpose approved drugs to decrease the burden of the COVID-19 (official name for the coronavirus disease) pandemic. as the FDA (U.S. Food and Drug Administration) approved antiviral drugs and anti-inflammatory drugs to arrest the cytokine storm, inducing the production of pro-inflammatory cytokines. Another view to solve these unprecedented challenges is to analyze the diverse nanotechnological approaches which are able to improve the COVID-19 pandemic. In this original minireview, as promising candidates we analyze the opportunity to develop biocompatible dendrimers as drugs themselves or as nanocarriers against COVID-19 disease. From the standpoint of COVID-19, we suggest developing dendrimers as shields against COVID-19 infection based on their capacity to be incorporated in several environments outside the patients and as important means to stop transmission of SARS-CoV-2.<\/jats:p>","DOI":"10.3390\/pharmaceutics13091513","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T22:34:01Z","timestamp":1632263641000},"page":"1513","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Functionalized Dendrimer Platforms as a New Forefront Arsenal Targeting SARS-CoV-2: An Opportunity"],"prefix":"10.3390","volume":"13","author":[{"given":"Serge","family":"Mignani","sequence":"first","affiliation":[{"name":"Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologique, Universit\u00e9 Paris Descartes, PRES Sorbonne Paris Cit\u00e9, CNRS UMR 860, 75006 Paris, France"},{"name":"CQM\u2014Centro de Qu\u00edmica da Madeira, MMRG, Campus da Penteada, Universidade da Madeira, 9020-105 Funchal, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6785-6645","authenticated-orcid":false,"given":"Xiangyang","family":"Shi","sequence":"additional","affiliation":[{"name":"CQM\u2014Centro de Qu\u00edmica da Madeira, MMRG, Campus da Penteada, Universidade da Madeira, 9020-105 Funchal, Portugal"},{"name":"College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai 201620, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrii","family":"Karpus","sequence":"additional","affiliation":[{"name":"Laboratoire de Chimie de Coordination du CNRS, 205 Route de Narbonne, CEDEX 4, 31077 Toulouse, France"},{"name":"Universit\u00e9 Toulouse 118 Route de Narbonne, CEDEX 4, 31077 Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Lentini","sequence":"additional","affiliation":[{"name":"Dipartimento di Farmacia\u2014Scienze del Farmaco, Universit\u00e0 degli Studi di Bari Aldo Moro, 70125 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Majoral","sequence":"additional","affiliation":[{"name":"Laboratoire de Chimie de Coordination du CNRS, 205 Route de Narbonne, CEDEX 4, 31077 Toulouse, France"},{"name":"Universit\u00e9 Toulouse 118 Route de Narbonne, CEDEX 4, 31077 Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/22221751.2020.1723441","article-title":"An emerging coronavirus causing pneumonia outbreak in Wuhan, China: Calling for developing therapeutic and prophylactic strategies","volume":"9","author":"Jiang","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e00133-20","DOI":"10.1128\/CMR.00133-20","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Systemic Infection","volume":"34","author":"Synowiec","year":"2021","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12967-020-02344-6","article-title":"Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant","volume":"18","author":"Pachetti","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4103\/ijp.IJP_115_20","article-title":"Drug targets for corona virus: A systematic review","volume":"52","author":"Prajapat","year":"2020","journal-title":"Indian J. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.drudis.2020.06.018","article-title":"Current and future therapeutical approaches for COVID-19","volume":"25","author":"Duan","year":"2020","journal-title":"Drug Discov. Today"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.drudis.2020.06.017","article-title":"Discovering small-molecule therapeutic against SARS-Cov-2","volume":"25","author":"Tiwari","year":"2020","journal-title":"Drug.Discov. Today"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1021\/acs.oprd.0c00233","article-title":"Quest for a COVID-19 Cure by Repurposing Small-Molecule Drugs: Mechanism of Action, Clinical Development, Synthesis at Scale, and Outlook for Supply","volume":"24","author":"Hughes","year":"2020","journal-title":"Org. Process Res. Dev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 vaccines at pandemic speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1126\/science.abb9332","article-title":"Rapid repurposing of drugs for COVID-19","volume":"368","author":"Guy","year":"2020","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1089\/adt.2020.996","article-title":"COVID-19 and drug repurposing tsunami","volume":"18","author":"Mucke","year":"2020","journal-title":"Assay Drug Dev. Technol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.4155\/fmc-2020-0204","article-title":"Anti-COVID drugs: Repurposing existing drugs or seach for new complex entities, strategies and perspectives","volume":"12","author":"Pawekzyk","year":"2020","journal-title":"Future Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"McKeigue, P.M., Kennedy, S., Weir, A., Bishop, J., McGurnaghan, S.J., McAllister, D., Robertson, C., Wood, R., Lone, N., and Murray, J. (2021). Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: The REACT-SCOT case-control study. BMC Med., 19.","DOI":"10.1186\/s12916-021-01907-8"},{"key":"ref_17","unstructured":"U.S. Department of Health and Human Services (2021, September 02). Trump Administration Announces Framework and Leadership for \u2018Operation Warp Speed\u2019, Available online: https:\/\/www.hhs.gov\/about\/news\/2020\/05\/15\/trump-administration-announces-framework-and-leadership-for-operation-warp-speed.html."},{"key":"ref_18","unstructured":"Boener, L.K. (CEN.ACS.ORG, 2021). The antivirals that weren\u2019t: Drug repurposing for COVID-19 produced misleading results, CEN.ACS.ORG."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"26895","DOI":"10.1039\/D0RA05821A","article-title":"Potential repurposed SARS-CoV-2 (COVID-19) infection drugs","volume":"10","author":"Mohamed","year":"2020","journal-title":"RSC Adv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"112932","DOI":"10.1016\/j.jep.2020.112932","article-title":"Identifying potential treatments of COVID-19 from Traditional Chinese Medicine (TCM) by using a data-driven approach","volume":"258","author":"Ren","year":"2020","journal-title":"J. Ethnopharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.18520\/cs\/v118\/i7\/1087-1092","article-title":"Molecular docking analysis of selected natural products from plants for inhibition of SARS-CoV-2 main protease","volume":"118","author":"Vishwarkarma","year":"2020","journal-title":"Curr. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.encep.2020.05.006","article-title":"Rupurposing chlorpromazine to treat COVID-19: The reCOVery study","volume":"46","author":"Plaze","year":"2020","journal-title":"L\u2019Enc\u00e9phale"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.drudis.2020.04.005","article-title":"Boosting the arsenal against COVID-19 through computational drug repurposing","volume":"25","author":"Ciliberto","year":"2020","journal-title":"Drug Discov. Today"},{"key":"ref_25","first-page":"2980","article-title":"Drug repurposing for coronavirus (COVID-19): In silico screening of know drugs against coronavirus 3CL hydrolase and protease enzymes","volume":"26","author":"Elmezayen","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_26","first-page":"3924","article-title":"Repurposing approved drugs asinhibitors of SARS-CoV-2-S-protein from molecular modeling and virtual screening","volume":"39","author":"Rocha","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Adem, S., Eyupogiu, V., Sarfraz, I., Rasul, A., and Ali, M. (2020). Identification of potent COVID-19 main protease (Mpro) inhibitors from natural polyphenols: An in-silico strategy unvells a hope against CORONA. Preprints, 2020030333.","DOI":"10.20944\/preprints202003.0333.v1"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"117652","DOI":"10.1016\/j.lfs.2020.117652","article-title":"In silico studies on therapeutic agents for COVID-19: Drug repurposing","volume":"252","author":"Shah","year":"2020","journal-title":"Life Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1111\/febs.15369","article-title":"Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing","volume":"17","author":"Glebov","year":"2020","journal-title":"FEBS J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s11095-020-02842-8","article-title":"Repurposing quaternary ammonium compounds as potential treatments for COVID-19","volume":"37","author":"Baker","year":"2020","journal-title":"Pharm. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41416-020-0948-x","article-title":"Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy","volume":"123","author":"Saini","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13046-020-01590-2","article-title":"Drug repurposing against COVID-19: Focus on anticancer agents","volume":"39","author":"Ciliberto","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"117477","DOI":"10.1016\/j.lfs.2020.117477","article-title":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19","volume":"248","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/jmv.25752","article-title":"Potentially repurposing adamantanes for COVID-19","volume":"92","author":"Cimolai","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e9357","DOI":"10.7717\/peerj.9357","article-title":"Host transcriptome-guided drug repurposing for COVID-19 treatment: A meta-analysis based approach","volume":"8","author":"Loganathan","year":"2020","journal-title":"PeerJ"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41586-021-03431-4","article-title":"Clofazimine broadly inhibits coronaviruses including SARS-CoV-2","volume":"593","author":"Yuan","year":"2021","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1021\/acs.molpharmaceut.0c01239","article-title":"siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses","volume":"18","author":"Sajid","year":"2021","journal-title":"Mol. Pharm."},{"key":"ref_38","unstructured":"(2021, September 02). Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent against SARS-CoV-2. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-initiates-phase-1-study-novel-oral-antiviral."},{"key":"ref_39","first-page":"e35","article-title":"Thalidomide combined with low-dose glucocorticoid in the treatment of COVID-19 Pneumonia","volume":"10","author":"Chen","year":"2020","journal-title":"Preprints"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.3389\/fimmu.2020.01248","article-title":"Thalidomine-revisited: Are COVID-19 patients going to be the latest victims of yet another theoritical drug-repurposing?","volume":"11","author":"Khalil","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cmi.2020.10.036","article-title":"Efficacy and safety of tocilizumab in COVID-19 patients: A living systematic review and meta-analysis","volume":"27","author":"Tleyjeh","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/thoraxjnl-2020-215266","article-title":"Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19","volume":"76","author":"Khan","year":"2021","journal-title":"Thorax"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3389\/fchem.2018.00360","article-title":"Nanomedicine: Principles, Properties, and Regulatory Issues","volume":"6","author":"Soares","year":"2018","journal-title":"Front. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/nano.2006.1.2.115","article-title":"Nanomedicine: What\u2019s in a definition?","volume":"1","author":"Webster","year":"2006","journal-title":"Int. J. Nanomed."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"15492","DOI":"10.1016\/j.matpr.2018.04.155","article-title":"Nanotechnology, Nanomedicine: Start small, think big","volume":"5","author":"Kargozara","year":"2018","journal-title":"Mater. Today Proc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1515\/bnm-2015-0030","article-title":"Smart multifunctional nanoparticles in nanomedicine","volume":"17","author":"Seleci","year":"2016","journal-title":"BioNanoMaterials"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/joim.12280","article-title":"Emerging concepts in dendrimer-based nanomedicine: From design principles to clinical applications","volume":"276","author":"Kannan","year":"2014","journal-title":"J. Intern. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Tomalia, D.A., Nixon, L.S., and Hedstrand, D.M. (2020). The Role of Branch Cell Symmetry and Other Critical Nanoscale Design Parameters in the Determination of Dendrimer Encapsulation Properties. Biomolecules, 10.","DOI":"10.3390\/biom10040642"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1055\/s-1978-24702","article-title":"Cascade and nonskid-chain-like syntheses of molecular cavity topologies","volume":"2","author":"Buhleier","year":"1978","journal-title":"Synthesis"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1295\/polymj.17.117","article-title":"A new class of polymers: Starburst-dendritic macromolecules","volume":"17","author":"Tomalia","year":"1985","journal-title":"Polym. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S1359-6446(01)01757-3","article-title":"Poly(amidoamine) (PAMAM) dendrimers: From biomimicry to drug delivery and biomedical applications","volume":"6","author":"Esfand","year":"2001","journal-title":"Drug Discov. Today"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.mtchem.2019.04.004","article-title":"Poly(amidoamine) dendrimers: Covalent and supramolecular synthesis","volume":"13","author":"Lyu","year":"2019","journal-title":"Mater. Today Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/1521-3773(20020415)41:8<1329::AID-ANIE1329>3.0.CO;2-P","article-title":"Dendritic polymers in biomedical applications: From potential to clinical use in diagnostics and therapy","volume":"41","author":"Stiriba","year":"2002","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.addr.2017.11.007","article-title":"Bench-to-bedside translation of dendrimers: Reality or utopia? A concise analysis","volume":"136\u2013137","author":"Mignani","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Chis, A.A., Dobrea, C., Morgovan, C., Arseniu, A.M., Rus, L.L., Butuca, A., Juncan, A.M., Totan, M., Vonica-Tincu, A.L., and Cormos, G. (2020). Applications and Limitations of Dendrimers in Biomedicine. Molecules, 25.","DOI":"10.3390\/molecules25173982"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/1556-276X-9-247","article-title":"Dendrimers: Synthesis, applications, and properties","volume":"9","author":"Abbasi","year":"2014","journal-title":"Nanoscale Res. Lett."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"507273","DOI":"10.1155\/2014\/507273","article-title":"Applications of Dendrimers in Drug Delivery Agents, Diagnosis, Therapy, and Detection","volume":"2014","author":"Bustos","year":"2014","journal-title":"J. Nanomater."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1021\/bc010102u","article-title":"Polyester dendritic systems for drug delivery applications: Design, synthesis, and characterization","volume":"13","author":"Ihre","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.ejmech.2007.12.021","article-title":"The effect of dendrimers on the pharmacodynamic and pharmacokinetic behaviors of non-covalently or covalently attached drugs","volume":"43","author":"Cheng","year":"2008","journal-title":"Eur. J. Med. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2217\/nnm.14.196","article-title":"Dendrimer-nanoparticle conjugates in nanomedicine","volume":"10","author":"Parat","year":"2015","journal-title":"Nanomedicine"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/nbt1171","article-title":"Designing dendrimers for biological applications","volume":"23","author":"Lee","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"113456","DOI":"10.1016\/j.ejmech.2021.113456","article-title":"First-in-class and best-in-class dendrimer nanoplatforms from concept to clinic: Lessons learned moving forward","volume":"219","author":"Mignani","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"8844030","DOI":"10.1155\/2021\/8844030","article-title":"Dendrimers: A New Race of Pharmaceutical Nanocarriers","volume":"2021","author":"Mittal","year":"2021","journal-title":"BioMed Res. Int."},{"key":"ref_66","first-page":"14","article-title":"Dendrimers as Nanocarriers in Cancer Chemotherapy","volume":"5","author":"Tomar","year":"2019","journal-title":"Int. J. Chem. Mol. Eng."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1021\/acsnano.0c03697","article-title":"Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic","volume":"14","author":"Weiss","year":"2020","journal-title":"ACS Nano"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2147\/IJN.S296383","article-title":"Application of Nanotechnology in the COVID-19 Pandemic","volume":"26","author":"Yang","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41565-020-0752-z","article-title":"Dexamethasone nanomedicines for COVID-19","volume":"15","author":"Lammers","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.2174\/0929867326666190827151741","article-title":"Intranasal nanoparticulate systems as alternative route of drug delivery","volume":"26","author":"Alshweiat","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1080\/03639045.2019.1583758","article-title":"Subunit-based mucosal vaccine delivery systems for pulmonary delivery are they feasible?","volume":"45","author":"Marasini","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0168-3659(93)90180-D","article-title":"Pulmonary delivery of liposomes","volume":"24","author":"Schreier","year":"1993","journal-title":"J. Control. Release"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1007\/s11051-009-9820-x","article-title":"Titanium dioxide-coated nanofibers for advanced filters","volume":"12","author":"Lee","year":"2010","journal-title":"J. Nanopart. Res."},{"key":"ref_74","unstructured":"(2021, September 02). Guardian G-Volt Masks Use Graphene and Electrical Charge to Repel Viruses. Available online: https:\/\/grapheneindustry.org.au\/2020\/05\/g-volt-mask\/."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Orlowski, P., Tomaszewska, E., Gniadek, M., Baska, P., Nowakowska, J., Sokolowska, J., Nowak, Z., Donten, M., Celichowski, G., and Grobelny, J. (2014). Tannic acid modified silver nanoparticles show antiviral activity in herpes simplex virus Type 2 infection. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0104113"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e01697-15","DOI":"10.1128\/mBio.01697-15","article-title":"Human coronavirus 229E remains infectious on common touch surface materials","volume":"6","author":"Warnes","year":"2015","journal-title":"mBio"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"14161","DOI":"10.1039\/D0RA01387K","article-title":"High antiviral activity of mercaptoethane sulfonate functionalized Te\/BSA nanostars against arterivirus and coronavirus","volume":"10","author":"Zhou","year":"2020","journal-title":"RSC Adv."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.1021\/acsnano.8b01616","article-title":"Multivalent Flexible Nanogels Exhibit Broad-Spectrum Antiviral Activity by Blocking Virus Entry","volume":"12","author":"Dey","year":"2018","journal-title":"ACS Nano"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"12522","DOI":"10.1021\/acsnano.0c07197","article-title":"Covid-19 vaccine frontrunners and their nanotechnology design","volume":"14","author":"Chung","year":"2020","journal-title":"ACS Nano"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s12026-020-09154-4","article-title":"Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development","volume":"68","author":"Calina","year":"2020","journal-title":"Immunol. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41563-020-0746-0","article-title":"Next-generation vaccine platforms for COVID-19","volume":"19","year":"2020","journal-title":"Nat. Mater."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Tenchov, R., Bird, R., Curtze, A.E., and Zhou, Q. (2021). Lipid Nanoparticles\u2014From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano.","DOI":"10.1021\/acsnano.1c04996"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40005-017-0370-4","article-title":"Nanomedicines: Current Status and Future Perspectives in Aspect of Drug Delivery and Pharmacokinetics","volume":"48","author":"Choi","year":"2018","journal-title":"J. Pharm. Investig."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1021\/acsptsci.0c00220","article-title":"COVID-19 evolution in the post-vaccination phase: Endemic or extinct?","volume":"4","author":"Fernadez","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.progpolymsci.2013.03.003","article-title":"Dendrimer space concept for innovative nanomedicine: A futuristic vision for medicinal chemistry","volume":"38","author":"Mignani","year":"2013","journal-title":"Prog. Polym. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Filipczak, N., Yalamarty, S.S.K., Li, X., Parveen, F., and Torchilin, V. (2021). Developments in Treatment Methodologies Using Dendrimers for Infectious Diseases. Molecules, 26.","DOI":"10.3390\/molecules26113304"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/mp2005033","article-title":"Exploiting dendrimer multivalency to combat emerging and reemerging infectious diseases","volume":"5","author":"Mintzer","year":"2012","journal-title":"Mol. Pharm."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Ortega, M.A., Merino, A.G., Fraile-Mart\u00ednez, O., Recio-Ruiz, J., Pekarek, L., Guijarro, L.G., Garc\u00eda-Honduvilla, N., \u00c1lvarez-Mon, M., Buj\u00e1n, J., and Garc\u00eda-Gallego, S. (2020). Dendrimers and Dendritic Materials: From Laboratory to Medical Practice in Infectious Diseases. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12090874"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.7150\/thno.46691","article-title":"Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients","volume":"10","author":"Itani","year":"2020","journal-title":"Theranostics"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/jmv.25928","article-title":"A pilot study of the antiviral activity of anionic and cationic polyamidoamine dendrimers against the Middle East respiratory syndrome coronavirus","volume":"92","author":"Kandeel","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1002\/ange.201913708","article-title":"Amphiphilic Polyphenylene Dendron Conjugates for Surface Remodeling of Adenovirus 5","volume":"132","author":"Wagner","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1021\/acsnano.0c02857","article-title":"Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2","volume":"14","author":"Han","year":"2020","journal-title":"ACS Nano"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1128\/AAC.47.12.3784-3788.2003","article-title":"Evaluations of Unformulated and Formulated Dendrimer-Based Microbicide Candidates in Mouse and Guinea Pig Models of Genital Herpes","volume":"47","author":"Bernstein","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Tyssen, D., Henderson, S.A., Johnson, A., Sterjovski, J., Moore, K., La, J., Zanin, M., Sonza, S., Karellas, P., and Giannis, M.P. (2010). Structure Activity Relationship of Dendrimer Microbicides with Dual Action Antiviral Activity. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012309"},{"key":"ref_96","unstructured":"StarPharma (2021, September 02). Available online: https:\/\/starpharma.com\/news\/328."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Paull, J.R.A., Heery, G.P., Bobardt, M.D., Castellarnau, A., Luscombe, C.A., Fairley, J.K., and Gallay, P.A. (2021). Virucidal and antiviral activity of astodrimer sodium 1 against SARS-CoV-2 in vitro. bioRxiv.","DOI":"10.21203\/rs.3.rs-440941\/v1"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.addr.2013.01.001","article-title":"Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: A Concise overview","volume":"35","author":"Mignani","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"112905","DOI":"10.1016\/j.ejmech.2020.112905","article-title":"Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: An opportunity to develop new CNS drugs","volume":"209","author":"Mignani","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jconrel.2015.07.024","article-title":"Nanotechnology approaches for inhalation treatment of lung diseases","volume":"219","author":"Kuzmova","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Gatti, M., and De Ponti, F. (2021). Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13030302"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"110288","DOI":"10.1016\/j.mehy.2020.110288","article-title":"Smart polymeric eye gear: A possible preventive measure against ocular transmission of COVID-19","volume":"144","author":"Sahua","year":"2020","journal-title":"Med. Hypotheses"},{"key":"ref_103","unstructured":"(2021, September 02). Pharmaceutical Business Review. Available online: https:\/\/www.pharmaceutical-business-review.com\/news\/orpheris-enrols-first-patients-in-phase-2-clinical-study-evaluating-op-101-for-severe-covid-19\/."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"155151","DOI":"10.1016\/j.cyto.2020.155151","article-title":"COVID-19 cytokine storm: The anger of inflammation","volume":"133","author":"Mahmudpour","year":"2020","journal-title":"Cytokine"},{"key":"ref_105","unstructured":"Kannan, S. (November, January 30). OP-101: A novel therapy for treatment of childhood cerebral adrenoleukodystrophy. Proceedings of the 3rd Annual Congress on Rare Diseases and Orphan Drugs, San Antonio, TX, USA. Available online: https:\/\/www.longdom.org\/proceedings\/op101-a-novel-therapy-for-treatment-of-childhood-cerebral-adrenoleukodystrophy-18784.html."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00604-021-04773-6","article-title":"A nanoscale genosensor for early detection of COVID-19 by voltammetric determination of RNA-dependent RNA polymerase (RdRP) sequence of SARS-CoV-2 virus","volume":"188","author":"Farzin","year":"2021","journal-title":"Microchim. Acta"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"106867","DOI":"10.1016\/j.spmi.2021.106867","article-title":"Sensitivity enhancement of a surface plasmon resonance sensor using Blue Phosphorene\/MoS2 hetero-structure and barium titanate","volume":"153","author":"Setareh","year":"2021","journal-title":"Superlattices Microstruct."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s42003-020-01615-8","article-title":"A comprehensive review on plasmonic-based biosensors used in viral diagnostics","volume":"4","author":"Shrivastav","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Gurunathan, S., Qasim, M., Choi, Y., Do, J.T., Park, C., Hong, K., Kim, J.-H., and Song, H. (2020). Antiviral Potential of Nanoparticles\u2014Can Nanoparticles Fight against Coronaviruses?. Nanomaterials, 10.","DOI":"10.3390\/nano10091645"},{"key":"ref_110","first-page":"1","article-title":"Deep-learning based repurposing of FDA-approved drugs against Candida albicans dihydrofolate reductase and molecular dynamics study","volume":"21","author":"Joshi","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"117627","DOI":"10.1016\/j.lfs.2020.117627","article-title":"Virtual screening and repurposing of FDA approved drugs against COVID-19","volume":"251","author":"Kandeel","year":"2020","journal-title":"Life Sci."},{"key":"ref_112","unstructured":"(2021, September 02). Mediphage in the News. Available online: https:\/\/www.mediphage.ca\/press."},{"key":"ref_113","unstructured":"Cross, R. (CEN.ACS.ORG, 2021). Stopping COVID-19 where it starts, CEN.ACS.ORG, 25\u201329."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"abc2782","DOI":"10.1126\/scirobotics.abc2782","article-title":"Repurposing factories with robotics in the face of COVID-19","volume":"5","author":"Malik","year":"2020","journal-title":"Sci. Robot."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"eaaz5466","DOI":"10.1126\/sciadv.aaz5466","article-title":"Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents","volume":"6","author":"Dormont","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s13346-020-00818-0","article-title":"Nanotechnology-based antiviral therapeutics","volume":"11","author":"Chakravarty","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fmolb.2020.00188","article-title":"Bioactive Virus-Mimicking Nanovesicles from Dendrimersomes: A Novel Approach to Understanding SARS-CoV-2 Host-Interactions to Better Design Therapeutics","volume":"21","author":"Javed","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"ref_118","unstructured":"(2021, September 02). Iran Leverages Nanotechnology to Launch West Asia\u2019s Largest Face Mask Production Plant. Available online: https:\/\/statnano.com\/news\/67581\/Iran-Leverages-Nanotechnology-to-Launch-West-Asia%E2%80%99s-Largest-Face-Mask-Production-Plant."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/9\/1513\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:02:06Z","timestamp":1760166126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/9\/1513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,18]]},"references-count":118,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["pharmaceutics13091513"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13091513","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,18]]}}}